Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 18
- Registration Number
- NCT00232570
- Locations
- 🇺🇸
Fletcher Allen Health Care-Clinical Neuroscience Research Unit, Burlington, Vermont, United States
Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2006-10-17
- Lead Sponsor
- Arthur P. Noyes Research Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00231101
- Locations
- 🇺🇸
Arthur P. Noyes Research Foundation, Norristown, Pennsylvania, United States
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT00232414
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT00221468
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Quetiapine in Social Anxiety Disorder
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-12-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 15
- Registration Number
- NCT00215254
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Comparative Study of New Medications for Psychosis in Adolescents
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00222495
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00223210
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 115
- Registration Number
- NCT00223249
- Locations
- 🇺🇸
The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 753
- Registration Number
- NCT00216476
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT00208819
- Locations
- 🇺🇸
Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.